Stock screenerAll disclosures →
EDGAR →
ZYME
Conviction 89HealthcareScan · Thu, Sep 24, 2026Zymeworks Inc. (ZYME) closed at $26.80 (-2.55%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 49, RS Rating 92, -13.7% from its 52-week high, +0.7% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
ZYME$26.80-2.55%
ResistanceSupportVol 14Vol MA14 720.52K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price26.80
Change-2.55%
Gap-0.04%
Rel volume1.56×
Avg volume702.66K
Avg $ vol19.49M
SMA 2027.82
SMA 5025.85
SMA 20025.08
Price vs 50+3.67%
Price vs 200+6.85%
MA stackbullish
50/200 cross—
Supertrendup · 25.95
RSI (14)49
MACD hist-0.18
MACD cross—
Stoch %K / %D24 / 29
ADX (14)24
+DI / −DI22 / 18
RSI divergence—
MACD divergenceBearish
ATR %4.63%
ADR %3.84%
52w high31.05
52w low16.16
From 52w high-13.69%
Above 52w low+65.84%
New 52w highNo
SqueezeOff
Bollinger width20.24%
%B0.32
Donchian pos17.90%
Donchian high31.34
Donchian low25.81
AVWAP (52w high)27.26
vs AVWAP high-1.68%
AVWAP (52w low)23.89
vs AVWAP low+12.19%
OBV trendDown
Chaikin MF (20)-0.10
Today vs 20d1.56×
Avg vol (14d)720.52K
Avg vol (20d)702.66K
Avg $ vol (20d)19.49M
Market cap1.9B
RS Rating92 / 99
RS 3m (vs SPY)+8.26%
RS 6m (vs SPY)-6.21%
RS line new highNo
Trend template8/8
Technical rank64.3
1 week-2.47%
1 month-2.44%
3 months+12.75%
6 months+10.61%
1 year+63.81%
YTD+0.68%
P/E-23.44
P/B23.66
P/S17.95
P/FCF-55.08
EPS-1.08
Div yield—
ROE-100.95%
ROA-20.44%
Debt/Eq—
Current6.32
EV/EBITDA—
Gross margin—
Net margin-76.56%
Rev growth38.87%
EPS growth33.88%
Price target40.20
Target upside50.00%
Analyst ratingBuy
Institutional172.77%
Ent. value1.72B
Revenue4.59M
Net income-45.02M
Gross profit—
Free cash flow-34.53M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out73.02M
Employees264
ListedFri, Apr 28, 2017
Free float45.96M
Float %62.3%
Short interest4.72M
Days to cover5.7d
Short volume58.5%
Squeeze score66 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.62 vs −$0.56
Last surprise-10.7% miss
Setup gradeA+
Conviction89 / 100
Pattern quality—
Tech rank64.3 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance30.98
Support23.56
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Zymeworks stock gains on merger approval and a $41 targetAD HOC NEWS · Sun, Sep 20, 2026
- Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from BrokeragesMarketBeat · Sun, Sep 20, 2026
Congress activity
Disclosed STOCK Act trades in ZYME
No recent disclosed trades by Congress in ZYME. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ZYME
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Schneider Paul R EVP, General Counsel · Stock Option (Right to Buy) · 2026-05-13 | Grant | 178K | $0 | 2026-05-13 | 2026-05-15 |
Schneider Paul R EVP, General Counsel · Restricted Stock Unit · 2026-05-13 | Grant | 119K | $0 | 2026-05-13 | 2026-05-15 |
Schayowitz Adam See Remarks · Performance Stock Unit · 2026-04-09 | Grant | 76K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Stock Option (Right to Buy) · 2026-04-09 | Grant | 70K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Restricted Stock Unit · 2026-04-09 | Grant | 47K | $0 | 2026-04-09 | 2026-04-10 |
Schayowitz Adam See Remarks · Stock Option (Right to Buy) · 2026-04-09 | Grant | 70K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Performance Stock Unit · 2026-04-09 | Grant | 76K | $0 | 2026-04-09 | 2026-04-10 |
Schayowitz Adam See Remarks · Restricted Stock Unit · 2026-04-09 | Grant | 47K | $0 | 2026-04-09 | 2026-04-10 |
SEC filings
EDGAR filings in ZYME · 5 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.